Poly ICLC in the treatment of postinfectious demyelinating encephalomyelitis.
Three weeks after a mild and presumably infectious illness, a 21-year-old man developed a CNS disorder characterized by involvement of the cerebellum, cerebrum, and brainstem. It progressed, sometimes stepwise, without remission, over five months to being bedfast with total spastic paraplegia, severe ataxia, and unintelligible dysarthric speech. The CSF showed increased levels of protein, IgG, and myelin basic protein, as well as five oligoclonal bands. Because of failure of the patient's condition to respond to prolonged prednisone therapy, poly ICLC was given intravenously weekly for 20 weeks (median dose, 100 microgram/kg). Improvement, evident after the first dose, progressed to the point of ambulation with some assistance. Even though the relation of the patient's marked recovery to poly ICLC therapy remains unproved, this experience provides reason for considering a possible therapeutic role of the drug in postinfectious demyelinating encephalomyelitis and perhaps in multiple sclerosis.
D000328:Adult; D002266:Carboxymethylcellulose Sodium / Q000627:therapeutic use* / Q000031:analogs & derivatives; D003711:Demyelinating Diseases / Q000188:drug therapy* / Q000209:etiology; D004679:Encephalomyelitis / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007239:Infections / Q000150:complications; D008297:Male; D008747:Methylcellulose / Q000031:analogs & derivatives*; D010455:Peptides / Q000627:therapeutic use*; D011070:Poly I-C / Q000627:therapeutic use*; D011107:Polylysine / Q000627:therapeutic use* / Q000031:analogs & derivatives
D010455:Peptides; D011107:Polylysine; C019531:poly ICLC; D008747:Methylcellulose; D002266:Carboxymethylcellulose Sodium; D011070:Poly I-C